The free portion of the STAT article presents a short roundup of biotech news and leads with a headline indicating that Novo may be getting a better deal than expected from Medicare’s Bridge program. The excerpt includes several other company trial updates and situates the headline among wider industry developments.
Key items presented in the publicly available excerpt include positive trial reports from Roche, Celldex Therapeutics, Ionis Pharmaceuticals, and Viking Therapeutics. The STAT excerpt, however, contains a subscriber paywall for the main investigative piece about Novo and Medicare’s Bridge program; the detailed reporting, evidence, and any quotations are accessible only to STAT+ subscribers.
The excerpt reports that Viking Therapeutics announced positive topline results from a Phase 2 maintenance study of its injectable obesity candidate, VK2735. According to the announcement linked in the excerpt, VK2735 was initially tested as a weekly treatment and appeared to retain efficacy when patients switched to every-other-week or monthly dosing schedules.
The STAT excerpt identifies VK2735 as a GLP-1–GIP agonist and frames this update as demonstrating the promise of alternative maintenance dosing regimens. No additional efficacy or safety data, numerical results, or patient population details are provided in the free text; the excerpt links to Viking’s press release for further company-provided information.
While the headline asserts that Novo may be benefiting more than expected from Medicare’s Bridge program, the substantive investigative reporting and supporting details are behind the STAT+ paywall. The excerpt does not include:
Because those elements are not present in the publicly available portion of the article, they cannot be reported or summarized here. The source explicitly notes that the rest of the story is exclusive to STAT+ subscribers.
The publicly accessible roundup also includes the following reported items:
Roche reported a positive Phase 2 trial of enicepatide (previously CT-388) in patients with type 2 diabetes and obesity. The excerpt states the drug helped patients lose weight and lower blood sugar, and that Roche already has two Phase 3 weight-loss studies underway. Roche plans to start an additional pivotal trial next year focusing on blood sugar control and cardiovascular outcomes, according to the linked company communication.
Celldex Therapeutics said an experimental treatment for chronic hives reached the goals of two Phase 3 clinical trials. The excerpt links to Celldex’s announcement about the positive Phase 3 results but does not provide trial details in the free text.
Ionis Pharmaceuticals reported positive Phase 3 topline results for an RNA-based therapy named ulefnersen in a rare form of amyotrophic lateral sclerosis (ALS). The excerpt states the drug prolonged survival and slowed disease progression in the Phase 3 trial and notes that the therapy is licensed to Otsuka. The available text links to Ionis’s press release for the topline results.
These items are presented as concise bullet points in the free excerpt and include links to company releases. The excerpt does not include detailed trial datasets, numerical outcomes, statistical analyses, or independent expert commentary.
The source makes clear that the in-depth reporting and analysis about Novo and the Medicare Bridge program are exclusive to STAT+ subscribers. To read the remainder of the article — which would presumably contain the investigative details, evidence cited, and any direct quotes or documents underpinning the headline claim — the excerpt directs readers to subscribe or log in.
Because the available source content is limited to the headline, a brief roundup of industry trial news, and a paywall notification, this rewrite refrains from asserting or extrapolating any additional facts about the alleged Novo–Medicare arrangement. Specifics about the alleged deal, Medicare program operations, and potential implications were not reported in the free excerpt and therefore are not included here.